All In Biotech

Free tool

FAERS Monitor: Yesafili

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761274 or its brand name (Yesafili, Aflibercept-Jbvf). Reports on generic versions are filed under their own applications.

Reports

16

Serious

15

94% of reports

Hospitalization

1

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye haemorrhage4
  • visual impairment3
  • drug ineffective2
  • eye pain2
  • lacrimation increased2
  • subretinal fluid2
  • vision blurred2
  • vitreous floaters2
  • blindness unilateral1
  • eye disorder1
  • eye swelling1
  • fall1
  • glaucoma1
  • headache1
  • inappropriate schedule of product administration1

Reports by year received

View as table
YearReports
202616

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,143 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
subretinal fluid22412.3658.92,706
eye haemorrhageSignal4394.2168.71,201
vitreous floaters2267.673.2298
blindness unilateral193.214.022
lacrimation increased287.023.895
glaucoma168.310.216
eye pain246.612.750
eye disorder140.06.09
eye swelling135.35.38
visual impairmentSignal331.811.562
vision blurred219.15.219
inappropriate schedule of product administration17.31.11
fall13.90.60
headache12.10.30
drug ineffective22.00.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.